IP Library Granted Patent US 9,895,189
Granted Patent B2
US 9,895,189 · App. 14/302,678 · Granted Feb 20, 2018

Methods of sterilization and treating infection using irreversible electroporation

Inventor: Robert Pearson (San Jose, CA)
Assignee: AngioDynamics, Inc.
A61B18/1477A61B2018/00577A61B2018/00613A61B2018/124A61B2018/1467A61B2034/252A61B2034/254
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,895,189
App. No.
14/302,678
Granted
Feb 20, 2018
Kind
B2
Abstract

A method for treating an infection using irreversible electroporation is presented. The method includes providing an ablation device that has at least one electrode and inserting the ablation device into a target tissue of a patient. The tissue at least partially surrounds the implanted medical device. The outer surface of the medical device is at least partially covered by infectious cells. The method also involves positioning at least one electrode in or near the implanted medical device and delivering electrical pulses to or near the implanted medical device sufficient to irreversibly electroporate the infectious cells.

Claims (14)

1. A method of treating an infection in patient, wherein the method comprises:

implanting an implanted medical device, wherein the implanted medical device is made of a conductive material and wherein the outer surface of the medical device is at least partially covered by infectious cells;

inserting an ablation device into a target tissue of the patient, the ablation device comprising at least one electrode, wherein the tissue at least partially surrounds the implanted medical device;

positioning the at least one electrode a pre-determined distance from the implanted medical device; and

delivering electrical pulses through the at least one electrode to or near the implanted medical device sufficient to irreversibly electroporate the infectious cells, the implanted medical device acting as a return electrode.

2. The method of claim 1 , wherein the implanted medical device is selected from the group comprising: a catheter, an artificial cartilaginous implant, a pacemaker, an implantable port, a stent, orthopedic prosthetic, PICC, implantable valve, spinal implant, tooth implant, and a filter.

3. The method of claim 1 , wherein the infectious cells comprise bacterial cells selected from the group comprising bacteremia, Staphylococcus epidermidis, Escherichia coli, Staphylococcus aureus, Streptococcus Mutans, Streptococcus Mitus, Streptococcus Salivarius , and Enterobacter Aerogenes.

4. A method of sterilizing an infected implanted medical device, wherein the method comprises:

implanting an implanted medical device, wherein the implanted medical device is made of a conductive material and wherein the outer surface of the medical device is at least partially covered by infectious cells;

inserting an ablation device into a target tissue of the patient, the ablation device comprising at least one electrode, wherein the tissue at least partially surrounds an implanted medical device and wherein the outer surface of the medical device is at least partially covered by infectious cells;

positioning the at least one electrode a pre-determined distance from the implanted medical device; and

delivering electrical pulses through the at least one electrode to or near the implanted medical device sufficient to irreversibly electroporate the infectious cells, thereby sterilizing the implanted medical device, the implanted medical device acting as a return electrode.

5. The method of claim 4 , wherein the implanted medical device is selected from the group comprising: a catheter, an artificial cartilaginous implant, a pacemaker, an implantable port, a stent, orthopedic prosthetic, PICC, implantable valve, spinal implant, tooth implant, and a filter.

6. The method of claim 4 , wherein the infectious cells comprise bacterial cells selected from the group comprising bacteremia, Staphylococcus epidermidis, Escherichia coli, Staphylococcus aureus, Streptococcus Mutans, Streptococcus Mitus, Streptococcus Salivarius , and Enterobacter Aerogenes.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Jun 8, 2023
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: ANGIODYNAMICS, INC.
Reel/Frame 063940/0362 →
SECURITY INTEREST Recorded Aug 31, 2022
From: ANGIODYNAMICS, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 061360/0668 →
RELEASE OF SECURITY INTEREST Recorded Aug 31, 2022
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: ANGIODYNAMICS, INC.
Reel/Frame 061363/0446 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 30, 2022
From: PEARSON, ROBERT M
To: ANGIODYNAMICS, INC.
Reel/Frame 060934/0932 →
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Jun 5, 2019
From: ANGIODYNAMICS, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 049371/0657 →
SECURITY INTEREST Recorded Nov 8, 2016
From: ANGIODYNAMICS, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 040613/0049 →
Continuity (2)
Provisional Application 61834471 · Jun 13, 2013
Related Publication 20140378964A1 · Dec 25, 2014